Clinical trial · Observational
India HIV-CervCa Project
Comparison of Treatment Adherence and Toxicities of HIV Positive Patients Versus HIV Negative Cervical Cancer Patients in India
NCT07167069CI-TRIAL-00094967completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260930-000001
Summary
Brief summary (as posted)
The investigators propose to prospectively study the difference in treatment (CTRT) completion and toxicities between HIV positive and HIV negative women in India with locally advanced cervical cancer receiving CTRT.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| HIV Negative | — | UNRESOLVED | — |
| HIV Positive | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- HIV Positive
- description
- Cervical Cancer Patients with HIV positive
- interventionNames
- Radiation: Radiation Therapy
- label
- HIV Negative
- description
- Cervical Cancer Patients with HIV negative
- interventionNames
- Radiation: Radiation Therapy
Primary outcomes (2)
- measure
- Completion Rates of Cancer Treatment
- timeFrame
- 2 years
- description
- To evaluate and compare the completion rates of cancer treatment in HIV positive cervical cancer patients and HIV negative cervical cancer patients. Treatment adherence is defined as receiving at least 5 cycles of weekly cisplatin chemotherapy and completion of all prescribed radiation (including brachytherapy) and chemotherapy within 8 weeks of treatment initiation.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with newly biopsy proven squamous carcinoma or adenocarcinoma of the uterine cervix, FIGO stage IB2-IIIB in whom curative CTRT is planned * Karnofsky performance status ≥ 70 * Patients with lower paraortic lymph nodes (below the level of L2 vertebra) * patients diagnosed with cervical cancer whom also HIV positive or HIV negative Exclusion Criteria: * patients with active tuberculosis
References
Publications (0)
Data not yet available
No reference posted for this study.